Bone Biologics Corp 2026年季度报告

FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File No.001-40899 Bone Biologics Corporation(Exact name of registrant as specified in its charter) 42-1743430 2 Burlington Woods Drive, Ste 100, Burlington, MA 01803(Address of principal executive offices and Zip Code) (781) 552-4452(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Common stock, $0.001 par value per shareWarrants to Purchase Common stock, $0.001 parvalue per share Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. ☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter periodthat the registrant was required to submit and post such files). ☒Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). As of May 14, 2026, there were 1,795,260 shares of the issuer’s common stock, $0.001 par value, outstanding. Bone Biologics Corporation- INDEX - PagePART I – FINANCIAL INFORMATION:Item 1. Financial Statements.F-1Unaudited Condensed Consolidated Financial StatementsUnaudited Condensed Consolidated Balance SheetsF-1Unaudited Condensed Consolidated Statements of OperationsF-2Unaudited Condensed Consolidated Statements of Stockholders’ EquityF-3Unaudited Condensed Consolidated Statements of Cash FlowsF-5Notes to Unaudited Condensed Consolidated Financial StatementsF-6Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations4Item 3. Quantitative and Qualitative Disclosures about Market Risk7Item 4. Controls and Procedures7PART II – OTHER INFORMATION:8Item 1. Legal Proceedings8Item 1A. Risk Factors8Item 2. Unregistered Sales of Equity Securities and Use of Proceeds8Item 3. Defaults Upon Senior Securities8Item 4. Mine Safety Disclosures8Item 5. Other Information8Item 6. Exhibits9Signatures102 NOTE ON FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Form 10-Q”) contains forward-looking statements. Such forward-looking statementsinclude those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are notstatements of historical fact. These forward-looking statements are based on our current expectations and projections about futureevents and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differmaterially from those expressed or implied in such statements. These forward-looking statements are subject to a number of risks,uncertainties and assumptions. For a more detailed listing of some of the risks and uncertainties facing the Company, please see ourAnnual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission(“SEC”) on March 2, 2026 and subsequent Quarterly Reports on Form 10-Q or other reports filed with the SEC. All statements other than historical facts contained in this report, including statements regarding our future financial position, capitalexpenditures, cash flows, business strategy and plans and objectives of management for future operations are forward-lookingstatements. The words “anticipate,” “believe,” “expect,” “future,” “plan,” “estimate,” “can,” “could,” “may,” “might,” “will,” “would,”and similar expressions are intended to identify forward-looking statements. These statements include, among others, informationregarding future operations, future capital expenditures, and future net cash flow. Such statements reflect o